Aldeyra Therapeutics, Inc to Post FY2027 Earnings of $0.22 Per Share, HC Wainwright Forecasts (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Research analysts at HC Wainwright upped their FY2027 EPS estimates for shares of Aldeyra Therapeutics in a report released on Monday, May 6th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology company will post earnings per share of $0.22 for the year, up from their previous estimate of $0.16. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ FY2028 earnings at $0.62 EPS.

Other equities analysts have also recently issued reports about the stock. StockNews.com cut shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. Oppenheimer reissued an “outperform” rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Monday.

Aldeyra Therapeutics Trading Down 2.4 %

NASDAQ:ALDX opened at $4.07 on Wednesday. The firm has a fifty day simple moving average of $3.72 and a 200 day simple moving average of $3.24. Aldeyra Therapeutics has a 1-year low of $1.42 and a 1-year high of $11.97. The stock has a market capitalization of $241.81 million, a PE ratio of -7.98 and a beta of 1.45.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.13.

Insider Activity at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, insider Bruce Greenberg sold 13,201 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $3.41, for a total value of $45,015.41. Following the transaction, the insider now directly owns 120,699 shares of the company’s stock, valued at $411,583.59. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, major shareholder Perceptive Advisors Llc bought 8,374 shares of the stock in a transaction dated Monday, April 1st. The shares were bought at an average cost of $3.25 per share, with a total value of $27,215.50. Following the completion of the transaction, the insider now directly owns 8,601,960 shares of the company’s stock, valued at $27,956,370. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Bruce Greenberg sold 13,201 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $3.41, for a total value of $45,015.41. Following the completion of the sale, the insider now directly owns 120,699 shares of the company’s stock, valued at $411,583.59. The disclosure for this sale can be found here. Insiders have purchased 355,933 shares of company stock worth $1,473,245 over the last ninety days. Insiders own 7.30% of the company’s stock.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Prime Capital Investment Advisors LLC bought a new position in Aldeyra Therapeutics in the 4th quarter valued at $35,000. SG Americas Securities LLC bought a new position in shares of Aldeyra Therapeutics during the 4th quarter worth $39,000. NorthRock Partners LLC bought a new position in shares of Aldeyra Therapeutics during the 4th quarter worth $42,000. Kingswood Wealth Advisors LLC bought a new position in shares of Aldeyra Therapeutics during the 1st quarter worth $49,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Aldeyra Therapeutics by 1,064.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 22,167 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 20,264 shares during the period. 59.71% of the stock is owned by hedge funds and other institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.